Skip to main content

Future of 3D Cell Culture in Drug Discovery

Globally, the 3D cell culture market is witnessing high growth due to factors such as rise in research and development investments, higher adoption, use of microfluidic technology, increasing focus on regenerative medicine, and use of 3D cell culture models for drug discovery and toxicology in vivo testing. In addition, rapid increase in the need for organ transplantation is further expected to propel the growth of this market in coming years. However, the budget restraints by laboratories, lack of experienced professionals, and lack of consistency in 3D cell culture products, cost and complexity, and ethical concerns using animal sources are affecting the growth of this market.
3D cell culture market is segmented into cancer cell research, cell based assays/toxicity screening, regenerative medicine/tissue engineering, in vivo applications for stem cells, 3D printing/microfluidics, and others. The cancer cell research segment is poised to witness the highest growth rate in this market due to their increasing adoption as it speeds up the cancer drug discovery process than traditional time-consuming and expensive animal models.
The 3D cell culture market is expected to reach USD 1,720.3 Million by 2022 from USD 570.4 Million in 2016 growing at a CAGR of 20.3%.
In coming years, regenerative and stem cell research market offer huge potential to the growth of this market. Major players are developing advanced assay kits which will reduce the cost and efforts required in the field of regenerative medicine research such as identification of diseases pathways, and evaluation of potential new drugs.
The 3D cell culture market is highly competitive with the presence of various players. Some of the major players operating in the market are Thermo Fisher (US), Corning (US), Lonza (Switzerland), Merck (Germany), ReproCELL (Japan), and InSphero (Switzerland). The other players operating in this market include Global Cell Solutions (US), Synthecon (US), 3D Biotek (US), Kuraray (Japan), Hamilton Company (US), Mimetas (Netherlands), Emulate (US), Nano3D Biosciences (US), and QGel (Switzerland).
Labels:

Comments

Post a Comment

Popular posts from this blog

Best Accounting Software to Kick-start the Business for Smaller Firms – Xero

  Xero Accounting Software is an online software mainly designed for the accounting needs of small business firms. The software can be operated from a PC, phone, tablet, or Mac to view the cash flows of the company in real-time. The software is for small business houses and hence it is simple to use yet smart so that the users can devote most of the time in other important areas of their business. USP of This Software: Xero accounting software offers accounting services to small business firms in a smarter way. Some of the USPs of the software the more than 800apps integrated into the software, secure encryption, support system better performance report generation, and others apart from the basic accounting services offered. Best Accounting Software for Medium-Sized Businesses@ https://blog.360quadrants.com/2020/best-accounting-software-for-medium-sized-businesses/ Xero Pricing Xero accounting software offers 30 days of free trial after which you can choose from any of the pri...
Post a Comment
Read more

Risk-based Monitoring Software Market | Key Factor in Clinical Trial | Market Growth Worth $511 million

  Growth in the risk based monitoring software market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials. However, the high implementation cost of RBM solutions is expected to restrain the growth of this market during the forecast period. RBM Software Market Dynamics: Impact Analysis 1. Increased outsourcing of clinical trial processes to CROs 2. Cost and time efficiency of RBM solutions 3. Increasing government funding and grants to support clinical trials 4. Increased pharmaceutical R&D spending 5. Initiatives to boost digital health to propel market growth The risk-based monitoring (RBM) software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102112429 Software Component: The sof...
Post a Comment
Read more

Cell Sorting Market

The global  cell sorting market  is projected to reach USD 247.4 Million by 2021, at a CAGR of 7.0% in the forecast period (2016-2021). Factors such as technological advancements in cell sorters, rising funding and investments for development of technologically advanced cell sorters, and growing adoption of cell sorting techniques in research activities are driving the growth of global Market. The market is further driven by factors such as the growing prevalence of HIV/AIDS and cancer, expanding pharmaceutical and biotechnology industries, and launch of specific reagents for specific applications. However, factors such as the high cost of instruments and lack of awareness & technical knowledge regarding the use of cell sorters are hampering the growth of market. Geographically, the market is segmented into North America, Europe, Asia-Pacific, and RoW. Among the four geographic regions, North America is estimated to command the largest share of the market in 2016, foll...
Post a Comment
Read more